A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Condition:   Chronic Myeloid Leukemia, Chronic Phase Interventions:   Drug: HQP1351;   Drug: Hydroxyurea or Interferon-based therapy;   Drug: Homoharringtonine;   Drug: Imatinib, Dasatinib or Nilotinib Sponsor:   Ascentage Pharma Group Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials